IP Library Granted Patent US 12698492
Granted Patent B2
US 12698492 · App. 18/652,819 · Granted Aug 4, 2026

Isolated CAS13 protein and use thereof

Inventors: Junbin Liang (Guangzhou, CN); Xingxiang Liang (Guangzhou, CN); Yang Sun (Shaoxing, CN); Hui Xu (Guangzhou, CN); Zhiqin Peng (Guangzhou, CN); Kaiwei Si (Guangzhou, CN); Desheng Huangfu (Guangzhou, CN)
Assignees: GUANGZHOU REFORGENE MEDICINE CO., LTD.; ZHEJIANG SYNSORBIO TECHNOLOGY CO., LTD
C12N9/22C12N15/11C12N15/907C12Q1/6816C12N2310/20C12N2320/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698492
App. No.
18/652,819
Granted
Aug 4, 2026
Kind
B2
Abstract

The present disclosure relates to an isolated Cas13 protein and use thereof. The amino acid sequence of the isolated Cas13 protein comprises a sequence having ≥50% sequence identity with the sequence as shown in any one of SEQ ID NO: 1-SEQ ID NO: 7, and SEQ ID NO: 60. The Cas13 protein is a Cas13 enzyme with an endonuclease activity, which can be used in a CRISPR/Cas system to achieve targeting and modification of a target nucleic acid, enriching the enzymes and systems available in a CRISPR-C as editing system.

Claims (4)

1 . A non-naturally occurring conjugate comprising a Cas13 protein and a nuclear localization signal and/or a nuclear export signal;

wherein the Cas13 protein comprises the amino acid sequence of SEQ ID NO: 3;

wherein the Cas13 protein has Cas13 nuclease activity and can form a complex with a gRNA to bind to a target nucleic acid in a non-bacterial cell.

2 . A composition comprising the conjugate of claim 1 and a gRNA capable of forming a complex with the conjugate.